Signaling pathways
-
BA7848 BAY-1436032Summary: A novel pan-mutant isocitrate dehydrogenase 1 inhibitor. - BA7849 GSK321Summary: GSK321 is a potent inhibitor of the mutant isocitrate dehydrogenase 1 enzyme.
- BA7850 OlutasidenibSummary: Olutasidenib (FT-2102) is an orally active, blood-brain barrier-crossing, selective and potent inhibitor of isocitrate dehydrogenase.
- BA7851 IDH-305Summary: IDH-305 is an oral, mutation-selective and brain-permeable inhibitor targeting the (R132) mutation.
- BA7852 DS-1001bSummary: DS-1001b is an orally active, hemocerebropermeable, potent (isocitrate dehydrogenase-1) mutant inhibitor.
- BA7853 IDH889Summary: IDH889 is an orally available, brain-permeable, variant- and mutation-specific inhibitor of isocitrate dehydrogenase.
- BA7854 KHK-IN-2Summary: KHK-IN-2 is a potent, selective inhibitor.
- BA7855 LDHA-IN-3Summary: LDHA-IN-3, a selenobenzene compound
-
BA7856 LDHA-IN-4Summary: AZ-33 is a selective inhibitor. - BA7857 LDH-IN-1Summary: LDH-IN-1 is a new pyrazole-based inhibitor of human lactate dehydrogenase.